The HighLife transseptal mitral valve replacement (TSMVR) device may be suitable for use in patients who have mitral regurgitation (MR) and no alternative therapy to cardiac surgery or other transcatheter treatment and are not responding to guideline-directed medical therapy (GDMT), a new study shows.